Alcolase banked €1.5M in Seed funding to advance its enzyme-based treatment for alcohol intolerance. The round was led by Ada Ventures, with participation from Delphinus Venture Capital and Antler.
The Copenhagen-based biotech develops an oral enzyme therapy designed to address ALDH2 deficiency, often referred to as "Asian Flush syndrome". The condition prevents the body from effectively breaking down acetaldehyde, a toxic byproduct of alcohol metabolism, leading to physical discomfort and increased long-term health risks.
Alcolase's solution works by neutralising acetaldehyde directly in the gut before it enters the bloodstream. This approach aims to alleviate immediate symptoms such as skin flushing and nausea while reducing the systemic damage associated with the enzyme deficiency, which affects an estimated 500 million people globally.
The fresh capital will be used to accelerate product development and move the therapy toward clinical applications. As European biotech increasingly targets underserved genetic metabolic conditions, Alcolase represents a shift toward preventative, consumer-accessible enzyme therapies.
Originally reported by Tech Funding News.